Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: A comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer

Neurogastroenterology and Motility

Volumn 20, Issue 5, 2008, Pages 557-565

  Hirata, T ^a   Keto, Y ^a   Nakata, M ^a   Takeuchi, A ^a   Funatsu, T ^a   Akuzawa, S ^a   Sasamata, M ^a   Miyata, K ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

5 HT3 receptor antagonist; Colonic hyperalgesia; Colonic nociceptive threshold; Diarrhoea; Irritable bowel syndrome; Restraint stress

Indexed keywords

ALOSETRON; CILANSETRON; LOPERAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE AGONIST; POLYCARBOPHIL; RAMOSETRON; SEROTONIN ANTAGONIST; TIQUIZIUM; TRIMEBUTINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COLON DILATATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; HYPERALGESIA; IMMOBILIZATION STRESS; INTESTINE PRESSURE; IRRITABLE COLON; MALE; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALGESICS, OPIOID; ANIMALS; COLON; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; MALE; MUSCARINIC ANTAGONISTS; POLYMERS; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; STRESS, PSYCHOLOGICAL;

EID: 42249111897     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01069.x     Document Type: Article

References (37)

1. Blackshaw LA, Gebhart GF. The pharmacology of gastrointestinal nociceptive pathways. Curr Opin Pharmacol 2002 2:642 9.
2. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004 141:1285 93.
3. 3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002 16:1357 66.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130:1480 91.
5. Pare P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006 28:1726 35.
6. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002 51 (Suppl. 1 i67 71.
7. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995 109:40 52.
8. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97:S7 26.
9. Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci 2007 104:263 73.
10. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000 355:1035 40.
11. Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States Study. Gastroenterology 2001 120:A217.
12. 3 receptor agonist, YM-31636, increases gastrointestinal motility without increasing abdominal pain. Eur J Pharmacol 2001 431:35 41.
13. Traub RJ, Pechman P, Iadarola MJ, Gebhart GF. Fos-like proteins in the lumbosacral spinal cord following noxious and non-noxious colorectal distention in the rat. Pain 1992 49:393 403.
14. 3 receptor in stress-induced defecation. J Pharmacol Exp Ther 1992 261:297 303.
15. Yamada T, Saito T, Takahara E, Nagata O. Disposition of polycarbophil calcium (HSR-237) in rats and dogs. Iyakuhin Kenkyu 1997 28:23 32.
16. 3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995 114:558 62.
17. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000 46:474 80.
18. Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol 2007 573:190 5.
19. 3 receptor in CRH-induce defecation in rats. Am J Physiol 1998 274:G827 31.
20. Gue M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997 9:271 9.
21. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994 107:271 93.
22. Schafer M, Mousa SA, Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol 1997 323:1 10.
23. Valentino RJ, Page M, Van Bockstaele E, Aston-Jones G. Corticotropin-releasing factor innervation of the locus coeruleus region: distribution of fibers and sources of input. Neuroscience 1992 48:689 705.
24. 3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol 2002 54:1055 63.
25. Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 2007 15:5 9.
26. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004 16:17 28.
27. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PA. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993 38:977 95.
28. Roman F, Pascaud X, Taylor JE, Junien JL. Interactions of trimebutine with guinea-pig opioid receptors. J Pharm Pharmacol 1987 39:404 7.
29. Yoshikawa M, Endo H, Ohnogi Y, Miura Y, Takahashi T, Harigaya S. Biological fate of trimebutine maleate (1) Absorption, distribution and excretion in rats, mice and dogs. Phamacometrics 1982 24:289 300.
30. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998 285:707 15.
31. Roman FJ, Lanet S, Hamon J et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther 1999 289:1391 7.
32. Verne GN, Sen A, Price DD. Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome. J Pain 2005 6:493 6.
33. Heykants J, Michiels M, Knaeps A, Brugmans J. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man. Arzneimittelforschung 1974 24:1649 53.
34. Sengupta JN, Su X, Gebhart GF. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996 111:968 80.
35. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999 64:2351 8.
36. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001 15:355 61.
37. Saito T, Mizutani F, Iwanaga Y, Morikawa K, Kato H. Laxative and anti-diarrheal activity of polycarbophil in mice and rats. Jpn J Pharmacol 2002 89:133 41.